Another thing, the price per vial to the Philip
Post# of 148292
(Total Views: 616)
Posted On: 04/17/2021 4:06:53 PM
Another thing,
the price per vial to the Philippines equates to $325 if a treatment is consider 4 shots, $650 per vial if a treatment is 2 shots. I am unclear at this point how many shots are in a treatment.
Also, the talk about a buyout is silly. We literally are on the verge of revenue and approval. We have over 60 indications LL will work on. The first approval is the most difficult. Once we are approved for covid, HIV will be shortly forthcoming. The revenues and experience our company gained from covid will lend itself to future approvals on so many indications. We will have the money to fund large trials. We will also have made many friends in the Philippines and Brazil that will be anxious to join our trials. Approvals will be much easier, the drug is the same. I foresee at least 3 approvals a year after we get our first out of the way.
This stock will reach three digits if everything we believe about this amazing molecule is true. For those of you that would be happy to get a buyout at $30 or $50 dollars, no worries. You will soon be able to sell all your shares for that amount. We have waited this long, why trade the goose that is about to lay golden eggs over and over for the next 12 years for a quick (albeit nice) short term gain.
For those that want NP gone, be careful what you wish for. We would be getting a buyout shortly thereafter, and most likely $20 a share would be on the high side.
GLTA longs
the price per vial to the Philippines equates to $325 if a treatment is consider 4 shots, $650 per vial if a treatment is 2 shots. I am unclear at this point how many shots are in a treatment.
Also, the talk about a buyout is silly. We literally are on the verge of revenue and approval. We have over 60 indications LL will work on. The first approval is the most difficult. Once we are approved for covid, HIV will be shortly forthcoming. The revenues and experience our company gained from covid will lend itself to future approvals on so many indications. We will have the money to fund large trials. We will also have made many friends in the Philippines and Brazil that will be anxious to join our trials. Approvals will be much easier, the drug is the same. I foresee at least 3 approvals a year after we get our first out of the way.
This stock will reach three digits if everything we believe about this amazing molecule is true. For those of you that would be happy to get a buyout at $30 or $50 dollars, no worries. You will soon be able to sell all your shares for that amount. We have waited this long, why trade the goose that is about to lay golden eggs over and over for the next 12 years for a quick (albeit nice) short term gain.
For those that want NP gone, be careful what you wish for. We would be getting a buyout shortly thereafter, and most likely $20 a share would be on the high side.
GLTA longs
(9)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼